Document Detail

Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.
MedLine Citation:
PMID:  20712263     Owner:  NLM     Status:  MEDLINE    
We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing seroconversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007. Overall, the mean time to HBsAg clearance was 9.4 +/- 4.5 months. Seroconversion occurred in all patients, after a mean time of 8.0 +/- 3.7 months. In HBeAg negative patients, mean time to HBsAg clearance and to seroconversion were 9.2 +/- 5.9 and 6.8 +/- 4.0 months, respectively. In HBeAg positive patients, mean time to HBsAg clearance and to seroconversion were 9.7 +/- 0.6 months and 10.0 +/- 2.6 months, respectively. In this case series, seroconversion was maintained and was observed both in HBeAg positive patients and in HBeAg negative patients. Therefore, it may be preliminarily suggested that treatment with entecavir could be associated to HBsAg seroconversion in a short period of time, in both HBeAg positive and HBeAg negative HBV patients.
G d'Ettorre; G Barbarini; F Corti; M Gobber; C Pastecchia; G L Ricci; M Siciliano; B E Annicchiarico; V Vullo
Related Documents :
19648823 - Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in...
17971713 - Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily hig...
10174313 - Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein th...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  14     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-08-17     Completed Date:  2010-09-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  551-4     Citation Subset:  IM    
Department of Infectious Diseases & Tropical Medicine, Sapienza University, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Guanine / analogs & derivatives*,  therapeutic use
Hepatitis B Surface Antigens / blood*
Hepatitis B e Antigens / blood*
Hepatitis B, Chronic / drug therapy*,  immunology
Middle Aged
Prospective Studies
Reg. No./Substance:
0/Antiviral Agents; 0/Hepatitis B Surface Antigens; 0/Hepatitis B e Antigens; 0/entecavir; 73-40-5/Guanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolation, identification and molecular characterization of Vibrio parahaemolyticus from fish sample...
Next Document:  Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatm...